75F40123C00184↗

Name: 75F40123C00184: Characterize Naloxones Clinical Use, Risks, Benefits, and Effectiveness for Reversing Opioid Overdoses in Pre-Hospital Settings. Using Qualitative and Quantitative Blood Toxicology Tests, Determine the Risks, Benefits, Effectiveness of High Dose Nal
Creator: SpendQuery

CHARACTERIZE NALOXONES CLINICAL USE, RISKS, BENEFITS, AND EFFECTIVENESS FOR REVERSING OPIOID OVERDOSES IN PRE-HOSPITAL SETTINGS. USING QUALITATIVE AND QUANTITATIVE BLOOD TOXICOLOGY TESTS, DETERMINE THE RISKS, BENEFITS, EFFECTIVENESS OF HIGH DOSE NAL

Definitive Contract · Food and Drug Administration · to American College of Medical Toxicology, Inc. (UEI SENNVSJDUES4) · data as of 2026-09-30

Obligated to date$4.01M4 actions

Current value$4.01Mwith options exercised

Period2023-09-25 → 2026-09-29up to 2027-09-29 with options

Up for re-bid: ends 2026-09-29. Recompete brief → · Teledyne Griffin G510X Service Agreement ↗

What it is

Product or service: Health R&D Services; Health Care - Other; Basic Research (PSC AN41)
Industry: All Other Professional, Scientific, and Technical Services (NAICS 541990)
Contracting office: Fda Office of Acq Grant Svcs (75F401)
Competition: Full and open competition · 1 offer received
Pricing: Cost no fee
How it was bought: Standalone contract
Where the work is: Montgomery, MD · district MD-08
Topics: opioids

Obligations by fiscal year

FY2023$996.4K

FY2024$846.4K

FY2025$867.3K

FY2026$1.30M

SpendQuery holds FY2023 on; earlier years are on USAspending.gov.

Subcontractors: where the money went next

No subawards reported for this award. Primes report subawards of $30,000 or more; many awards have none.

Every action

4 actions since 2023-09-25. Each is a modification or amendment with the money it added or took back.

Date	Modification	Kind	Amount	What the agency wrote
2026-07-23	P00003	Option exercised	$1.30M	CHARACTERIZE NALOXONES CLINICAL USE, RISKS, BENEFITS, AND EFFECTIVENESS FOR REVERSING OPIOID OVERDOSES IN PRE-HOSPITAL SETTINGS. USING QUALITATIVE AND QUANTITATIVE BLOOD TOXICOLOGY TESTS, DETERMINE THE RISKS, BENEFITS, EFFECTIVENESS OF HIGH DOSE NAL
2025-08-12	P00002	Option exercised	$867.3K	CHARACTERIZE NALOXONES CLINICAL USE, RISKS, BENEFITS, AND EFFECTIVENESS FOR REVERSING OPIOID OVERDOSES IN PRE-HOSPITAL SETTINGS. USING QUALITATIVE AND QUANTITATIVE BLOOD TOXICOLOGY TESTS, DETERMINE THE RISKS, BENEFITS, EFFECTIVENESS OF HIGH DOSE NAL
2024-08-14	P00001	Funding only	$846.4K	CHARACTERIZE NALOXONES CLINICAL USE, RISKS, BENEFITS, AND EFFECTIVENESS FOR REVERSING OPIOID OVERDOSES IN PRE-HOSPITAL SETTINGS. USING QUALITATIVE AND QUANTITATIVE BLOOD TOXICOLOGY TESTS, DETERMINE THE RISKS, BENEFITS, EFFECTIVENESS OF HIGH DOSE NAL
2023-09-25	0		$996.4K	CHARACTERIZE NALOXONES CLINICAL USE, RISKS, BENEFITS, AND EFFECTIVENESS FOR REVERSING OPIOID OVERDOSES IN PRE-HOSPITAL SETTINGS. USING QUALITATIVE AND QUANTITATIVE BLOOD TOXICOLOGY TESTS, DETERMINE THE RISKS, BENEFITS, EFFECTIVENESS OF HIGH DOSE NAL

Source: USAspending.gov prime award transactions and FSRS subaward reports, as loaded by SpendQuery (data as of 2026-09-30). Amounts are obligations (money committed), not outlays. The official record on USAspending.gov ↗